|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500107979 |
|
最近更新日期: Date of Last Refreshed on: |
2025-08-21 17:17:19 |
|
注册时间: Date of Registration: |
2025-08-21 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
脑影像人工智能技术在超早期预测轻度认知障碍及病因分析中的应用 |
|
Public title: |
Brain Imaging Artificial Intelligence Technology in Early Prediction of Dementia and Etiological Analysis |
|
注册题目简写: |
中国轻度认知障碍双向队列研究 |
|
English Acronym: |
CBCS-MCI |
|
研究课题的正式科学名称: |
脑影像人工智能技术在超早期预测轻度认知障碍及病因分析中的应用 |
|
Scientific title: |
Brain Imaging Artificial Intelligence Technology in Early Prediction of Dementia and Etiological Analysis |
|
研究课题代号(代码): Study subject ID: |
2021RQ029, 2023RY019, 2024-MSLH-072 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王超 |
研究负责人: |
刘金洁 |
|
Applicant: |
Chao Wang |
Study leader: |
Jinjie Liu |
|
申请注册联系人电话: Applicant telephone: |
+86 411 8441 2001 |
研究负责人电话:
Study leader's |
+86 411 8441 2001 |
|
申请注册联系人传真 : Applicant Fax: |
+86 411 84411941 |
研究负责人传真: Study leader's fax: |
+86 411 84411941 |
|
申请注册联系人电子邮件: Applicant E-mail: |
vip2ljj@163.com |
研究负责人电子邮件: Study leader's E-mail: |
vip2ljj@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
https://www.dlzxyy.com/ |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
https://www.dlzxyy.com/ |
|
申请注册联系人通讯地址: |
辽宁省大连市沙河口区西南路826号大连理工大学附属中心医院 |
研究负责人通讯地址: |
辽宁省大连市沙河口区西南路826号大连理工大学附属中心医院 |
|
Applicant address: |
Central Hospital of Dalian University of Technology, No. 826, Xinan Road, Shahekou District, Dalian 116000, China |
Study leader's address: |
Central Hospital of Dalian University of Technology, No. 826, Xinan Road, Shahekou District, Dalian 116000, China |
|
申请注册联系人邮政编码: Applicant postcode: |
116033 |
研究负责人邮政编码: Study leader's postcode: |
116033 |
|
申请人所在单位: |
大连理工大学附属中心医院(大连市中心医院) |
||
|
Applicant's institution: |
Central Hospital of Dalian University of Technology |
||
|
研究负责人所在单位: |
大连理工大学附属中心医院(大连市中心医院) |
||
|
Affiliation of the Leader: |
Central Hospital of Dalian University of Technology |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
YN2023-011-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
大连理工大学附属中心医院(大连市中心医院)伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Central Hospital of Dalian University of Technology |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-07 00:00:00 | ||
|
伦理委员会联系人: |
姚洋 |
||
|
Contact Name of the ethic committee: |
Yang Yao |
||
|
伦理委员会联系地址: |
辽宁省大连市沙河口区西南路826号大连理工大学附属中心医院 |
||
|
Contact Address of the ethic committee: |
Central Hospital of Dalian University of Technology, No. 826, Xinan Road, Shahekou District, Dalian 116000, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 411 8441 2001 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
大连理工大学附属中心医院(大连市中心医院) |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Central Hospital of Dalian University of Technology |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
辽宁省大连市沙河口区西南路826号大连理工大学附属中心医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
Central Hospital of Dalian University of Technology, No. 826, Xinan Road, Shahekou District, Dalian 116000, China |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
大连市高层次人才创新支持计划,2021RQ029,2023RY019;辽宁省联合基金,2024-MSLH-072 |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
Dalian High level Talent Innovation Support Program,,2021RQ029,2023RY019 |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
轻度认知障碍 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Mild Cognitive Impairment |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
6D71 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
6D71 |
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
本研究拟探索老年痴呆早期预测方法及特异性影像学病因筛查标记物为主要目的,并指定靶向预防及干预措施,以达到延缓或防止认知障碍进展的最终目的,最大程度减轻社会经济负担。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
The main aim of this study is to explore methods of early prediction of dementia and specific imaging markers for screening the etiologies, and to specify targeted prevention and intervention measures. The ultimate goal is to delay or prevent the progression of cognitive impairment and minimise the socio-economic burden. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
1.年龄≥18岁; 2.利用简易精神状态筛查量表(Mini-Mental State Examination, MMSE)、蒙特利尔认知测验量表(Montreal Cognitive Assessment, MoCA)筛查出认知障碍或常规筛查认知功能正常患者; 3.对于依据美国《精神疾病的诊断和统计手册》(Diagnostic and Statistical Manual of Mental Disorders-V,DSM-V)确诊认知障碍患者,向前追溯至首次筛查出轻度认知功能障碍(MCI筛查依据教育程度调整的MMSE和 MoCA分界值)时间,自该日起向前回顾性收集3年以上临床及影像学资料(动态),且资料完整者,对照组向前追溯有3年以上动态就诊史,临床及影像动态资料完整者; 4.预期寿命≥3年; 5.患者或家属知情同意。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1. Age >= 18 years; 2. Patients with cognitive impairment or normal cognitive function screened by Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA); 3. For patients diagnosed with cognitive impairment according to the Diagnostic and Statistical Manual of mental Disorders-V (DSM-V) of the United States, trace back to the first screening of mild cognitive impairment (identified by educational based MMSE and MoCA scores). From that date, the clinical and imaging data (dynamic) of more than 3 years were retrospectively collected, and the data were complete. The control group had a dynamic medical history of more than 3 years, and the clinical and imaging dynamic data were complete; 4. Life expectancy >= 3 years; 5. Informed consent of patients or family members. |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1.虽确诊认知障碍,但无法确定确诊轻度认知障碍时间的患者; 2.特殊不可控因素导致认知障碍:脑肿瘤、脑外伤、手术、急性感染、中毒、副肿瘤综合征等; 3.严重全身性疾病; 4.代谢性疾病可能导致认知障碍:如甲状腺功能异常(如甲亢或甲减)、维生素B12缺乏、酒精中毒等,这些疾病可能导致可逆性认知障碍; 5.长期使用影响认知功能的药物:如镇静剂、抗胆碱能药物、抗癫痫药物等,这些药物可能对认知功能产生负面影响; 6.已参与其他干预性临床试验。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with an undetermined time of diagnosis of mild cognitive impairment; 2. Cognitive dysfunction caused by special uncontrollable factors: such as brain tumor, brain injury, surgery, acute infection, poisoning, paraneoplastic syndrome, etc; 3.Severe systemic diseases; 4. Reversible cognitive dysunction caused by metabolic diseases: such as thyroid dysfunction, vitamin B12 deficiency, alcoholism, etc.; 5. Cognitive dysfunction caused by long-term use of drugs: such as sedatives, anticholinergic drugs, antiepileptic drugs, etc.; 6. Patients participated in other interventional clinical trials. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-08-01 00:00:00至 To 2030-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-09-01 00:00:00 至 To 2030-08-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
/none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
公开原始数据日期:2030.08.30;公开原始数据方式:本地部署的数据库平台。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Publication date of raw data: 08/30/2030; Method of raw data publication: Locally deployed database platform. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |